Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical Trials

Jodi T Williams,Martin H Bolli,Christine Brotschi,Thierry Sifferlen,Michel A Steiner,Alexander Treiber,John Gatfield,Christoph Boss
DOI: https://doi.org/10.1021/acs.jmedchem.3c01894
IF: 8.039
2024-02-09
Journal of Medicinal Chemistry
Abstract:The orexin system consists of two neuropeptides (orexins A and B) and two receptors (OX1 and OX2). Selective OX1 receptor antagonists (SO1RA) are gaining interest for their potential use in the treatment of CNS disorders, including substance abuse, eating, obsessive compulsive, or anxiety disorders. While blocking OX2 reduces wakefulness, the expected advantage of selectively antagonizing OX1 is the ability to achieve clinical efficacy without the promotion of sleep. Herein we report our...
chemistry, medicinal
What problem does this paper attempt to address?